NCT02673138View on ClinicalTrials.gov

Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

January 31, 2017

Study Completion Date

July 31, 2017

Conditions

Type 1 Diabetes

Interventions

DRUG

canagliflozin

basal interruption with canagliflozin

OTHER

basal interruption without canagliflozin

basal interruption

Trial Locations (1)

06520

Yale University School of Medicine, New Haven

All Listed Sponsors

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Yale University

OTHER

NCT02673138 - Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion | Biotech Hunter | Biotech Hunter